Most U.S. CKD Patients Receive Renal Replacement Therapy

This article originally appeared here.
Share this content:
Most U.S. CKD Patients Receive Renal Replacement Therapy
Most U.S. CKD Patients Receive Renal Replacement Therapy

FRIDAY, Sept. 23, 2016 (HealthDay News) -- Most U.S. patients with advanced chronic kidney disease receive renal replacement therapy (RRT), according to a study published online Sept. 22 in the Clinical Journal of the American Society of Nephrology.

Susan P.Y. Wong, M.D., from the University of Washington in Seattle, and colleagues conducted a retrospective study involving 28,568 adults receiving care within the U.S. Department of Veterans Affairs who had a sustained estimated glomerular filtration rate <15 mL/min/1.73m².

Based on administrative data, the researchers found that 67.1 percent of cohort members received RRT during follow-up; of the remaining patients, chart review showed that an additional 7.5 percent received dialysis, 10.9 percent were preparing for and/or discussing dialysis, and 14.5 percent had made a decision not to pursue dialysis. The proportion of patients who received or were preparing to receive RRT varied, from 96.2 to 53.3 percent for those aged <45 years and those aged ≥85 years, respectively. After stratification by tertile of Gagne comorbidity score the results were similar.

"In this large U.S. cohort of patients with advanced CKD, the majority received, or were preparing to receive RRT," the authors write. "This was true even among the oldest patients with the highest burden of comorbidity."

One author disclosed receiving royalties from UpToDate.

Abstract
Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »


Sign up for myCME e-newsletters


Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions

More in Home

FDA Approves Bavencio for Merkel Cell Carcinoma

FDA Approves Bavencio for Merkel Cell Carcinoma

Drug targets the PD-1/PD-L1 pathway; first sanctioned treatment in the United States

Heterogeneous Association for Alcohol, CVD Presentation

Heterogeneous Association for Alcohol, CVD Presentation

Non-drinking linked to increased risks of unstable angina, MI, heart failure, ischemic stroke, PAD, AAA

Mobile App Cuts In-Person Visits After Breast Reconstruction

Mobile App Cuts In-Person Visits After Breast Reconstruction

Number of visits down, increase in e-mails to doctors for ambulatory patients undergoing breast recon

is free, fast, and customized just for you!

Already a member?

Sign In Now »